Pharmaceutical Executive-05-01-2016

Pharmaceutical Executive

Pharm Exec’s 10th annual Brand of the Year is Bristol-Myers Squibb’s Opdivo, which has raced into the lead position in the treatment-shifting immuno-oncology space behind launches in three key cancers-melanoma, lung, and renal.

Pharmaceutical Executive

A conversation with GlaxoSmithKline's US Pharmaceuticals head Jack Bailey.

Pharmaceutical Executive

A look at this year’s 2016 Pharm Exec Brand of the Year and it would seem that the industry has much to be optimistic about. But a look at the winner and runner-up for our “Anti-Brand of the Year” award clarifies how many outside of the industry really see it.

Pharmaceutical Executive
Features

May 05, 2016

An “how to” primer for life sciences companies on applying end-to-end evidence strategies in demonstrating product value.

Pharmaceutical Executive
From the Editor

May 04, 2016

The Boston biotech cluster proved an ideal setting for Pharm Exec's recent annual Editorial Advisory Board meeting, with the prevailing message that even the best environments for innovation require constant nurturing.

Pharmaceutical Executive

Policymakers seek to limit prescribing while also encouraging innovative R&D.

Pharmaceutical Executive
Special Sponsored Section

May 01, 2016

while France remains a global force in the pharmaceutical, medical device, and vaccines fields-and continues to tout a solid manufacturing base and re-exportation culture-questions are arising over the long- term sustainability of the country’s healthcare system and its traditionally generous public health provisions.

Issue PDF
Pharmaceutical Executive

May 01, 2016

Click the title above to open the Pharmaceutical Executive May 2016 issue in an interactive PDF format.

Column
Pharmaceutical Executive

April 27, 2016

Policymakers seek to limit prescribing while also encouraging innovative R&D.